Rajesh B Parekh Net Worth

The estimated Net Worth of Rajesh B Parekh is at least $2.9 Tisíc dollars as of 13 May 2021. Rajesh Parekh owns over 2,466,666 units of Eloxx Pharmaceuticals Inc stock worth over $2,896 and over the last 15 years Rajesh sold ELOX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Rajesh Parekh ELOX stock SEC Form 4 insiders trading

Rajesh has made over 2 trades of the Eloxx Pharmaceuticals Inc stock since 2010, according to the Form 4 filled with the SEC. Most recently Rajesh bought 2,466,666 units of ELOX stock worth $3,329,999 on 13 May 2021.

The largest trade Rajesh's ever made was buying 2,466,666 units of Eloxx Pharmaceuticals Inc stock on 13 May 2021 worth over $3,329,999. On average, Rajesh trades about 358,095 units every 556 days since 2009. As of 13 May 2021 Rajesh still owns at least 4,827,129 units of Eloxx Pharmaceuticals Inc stock.

You can see the complete history of Rajesh Parekh stock trades at the bottom of the page.

What's Rajesh Parekh's mailing address?

Rajesh's mailing address filed with the SEC is C/O ELOXX PHARMACEUTICALS, INC, 480 ARSENAL WAY, SUITE 130, WATERTOWN, MA, 02472.

Insiders trading at Eloxx Pharmaceuticals Inc

Over the last 7 years, insiders at Eloxx Pharmaceuticals Inc have traded over $0 worth of Eloxx Pharmaceuticals Inc stock and bought 22,391,804 units worth $47,296,070 . The most active insiders traders include Ran Nussbaum, Tomer Kariv a Steven D Rubin. On average, Eloxx Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $275. The most recent stock trade was executed by Alan Edmund Walts on 1 December 2021, trading 37,695 units of ELOX stock currently worth $23.

What does Eloxx Pharmaceuticals Inc do?

eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin

Complete history of Rajesh Parekh stock trades at Celldex Therapeutics a Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc executives and stock owners

Eloxx Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Gregory Williams,
  Chief Executive Officer, Director
• Martijn Kleijwegt,
  Independent Director
• Steven Rubin,
  Independent Director
• Ran Nussbaum,
  Independent Director
• Zafrira Avnur,
  Independent Director
• Jasbir Seehra,
  Independent Director
• Gadi Veinrib,
  Independent Director
• Tomer Kariv,
  Independent Chairman of the Board
• Silvia Noiman,
  Director
• Stephen MacDonald,
  Principal Accounting Officer, Vice President - Finance and Accounting, Treasurer
• Neil Belloff,
  Chief Operating Officer, General Counsel, Corporate Secretary
• Matthew Goddeeris Ph.D.,
  VP of Research
• Dr. Ali Hariri M.D.,
  Chief Medical Officer
• Dr. Vijay Modur MBBS, Ph.D.,
  Head of R&D
• Rose Villandry,
  VP of HR
• Barbara Ryan,
  Investor Relations Officer
• Daniel E. Geffken M.B.A., MBA,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Sumit Aggarwal M.B.A.,
  Pres, CEO & Director
• David P. Snow,
  
• Robert Ward,
  
• Management 4 G.P. (2015) Lt...,
  
• Management 4 G.P. (2015) Lt...,
  
• Management Iii G.P. (2011) ...,
  
• Gilad Shabtai,
  10% owner
• Management 4 G.P. (2015) Lt...,
  
• Gregory L Weaver,
  
• Sumit Aggarwal,
  PRESIDENT AND CEO
• Vijay Modur,
  HEAD OF R&D
• Rajesh B Parekh,
  Director
• Daniel E. Geffken,
  INTERIM CFO
• Lindsay Androski,
  Director
• Alan Edmund Walts,
  Director